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   IgA	  nephropathy	  is	  one	  of	  the	  most	  common	  kidney	  diseases	  worldwide.	  
Most	  IgA	  nephropathy	  patients	  will	  undergo	  a	  kidney	  transplant	  as	  a	  treatment.	  
Treatment	  currently	  includes	  the	  use	  of	  immunosuppressants	  which	  are	  necessary	  
to	  prevent	  graft	  rejection	  but	  present	  harmful	  side-­‐effects	  when	  taken	  long-­‐term.	  
This	  review	  focuses	  on	  strategies	  which	  have	  the	  ability	  to	  promote	  tolerance	  of	  
both	  donor	  and	  recipient	  cells	  within	  a	  transplant	  recipient.	  Such	  strategies	  allow	  
development	  of	  mixed	  chimerism	  and	  thereby	  alleviate	  the	  need	  for	  long-­‐term	  
immunosuppressant	  usage	  in	  allograft	  recipients.	  These	  strategies	  could	  be	  applied	  
to	  IgA	  nephropathy	  patients	  to	  allow	  kidney	  allograft	  acceptance	  without	  the	  use	  of	  
long-­‐term	  immunosuppressant	  usage.	  These	  strategies	  may	  prevent	  recurrence	  of	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CD34	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  34	  (Adhesion	  Factor	  on	  Prothymocytes)	  	  
CD38	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  38	  (Cyclic	  ADP	  Ribose	  Hydrolase)	  
CD4	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  4	  	  	  (Glycoprotein	  on	  Helper	  T-­‐cells)	  
CD5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  5	  	  	  	  (B1-­‐cell	  and	  T-­‐cell	  protein)	  
CD59	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  59	  (Complement	  Regulatory	  Protein)	  
CD8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cluster	  of	  Differentiation	  8	  	  	  (Co-­‐receptor	  on	  Cytotoxic	  T-­‐cells)	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  Control	  Subjects	  
Da	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Daltons	  
ES	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Embryonic	  Stem	  Cells	  
Fab	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fragment	  Antigen	  Binding	  Region	  (	  Binds	  an	  Antibody	  to	  Antigen)	  
	  Fc	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fragment	  Crystallizable	  Region	  (Antibody	  Portion	  that	  Interacts	  with	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Cell	  Surface	  Receptors)	  
FcRn	  	  	  	  	  	  	  	  	  	  	  	  	  Neonatal	  Fragment	  Crystallizable	  Receptor	  (Neonatal	  Fc	  Receptor	  that	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Recycles	  IgG)	  	  	  	  
GCSF	  	  	  	  	  	  	  	  	  	  	  	  Granulocyte	  Colony	  Stimulating	  Factor	  (Stimulates	  Granulocyte	  and	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Stem	  Cell	  Production	  in	  Bone	  Marrow)	  
HLA	  	  	  	  	  	  	  	  	  	  	  	  	  	  Human	  Leukocyte	  Antigen	  
HSC	  	  	  	  	  	  	  	  	  	  	  	  	  	  Hematopoietic	  Stem	  Cell	  (Multipotent	  Cells	  that	  Produce	  Blood	  Cells)	  
IgA	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Immunoglobulin	  A	  
IgA-­‐BR	  	  	  	  	  	  	  Immunoglobulin	  A	  Binding	  Region	  (IgA	  Binding	  Region	  on	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Streptococcal	  Pyogenes	  M	  Protein)	  
IgA1	  	  	  	  	  	  	  	  	  	  	  	  Immunoglobulin	  A	  Type	  One	  
IgA2	  	  	  	  	  	  	  	  	  	  	  	  Immunoglobulin	  A	  Type	  Two	  
IgAN	  	  	  	  	  	  	  	  	  	  	  	  IgA	  Nephropathy	  
IgG	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Immunoglobulin	  G	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KB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Kidney	  Biopsy	  
KTX	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Kidney	  Transplant	  
Lin	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Lineage	  Commitment	  (Hematopoetic	  Stem	  Cells	  that	  are	  Negative	  for	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Lineage	  Specific	  Marker)	  
LTSC	  	  	  	  	  	  	  	  	  	  	  	  	  Long	  Term	  Stem	  Cell	  
PB	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Peripheral	  Blood	  
PBSC	  	  	  	  	  	  	  	  	  	  	  	  	  Peripheral	  Blood	  Stem	  Cells	  
PE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Peritoneal	  Fluids	  
Rh	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Rhesus	  Factor	  (Antigen	  on	  Red	  Blood	  Cells)	  
SLE	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Systemic	  Lupus	  Erythematosus	  
STPC	  	  	  	  	  	  	  	  	  	  	  	  	  Short	  Term	  Progenitor	  Cell	  
Thy1	  	  	  	  	  	  	  	  	  	  	  	  	  Thymocyte	  Differentiation	  Antigen	  (glycophosphatidylinositol anchored  
                            protein on prothymocytes) 
TREC	  	  	  	  	  	  	  	  	  	  	  	  	  T-­‐cell	  Receptor	  Excision	  Circles	  (Markers	  of	  Thymic	  T-­‐cell	  Emigrants)	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                                               I. OBJECTIVE 
 
  The purpose of this study is to review alternative methods to minimize or prevent 
long-term immunosuppressant usage in kidney transplant patients. This review focuses 
on developing strategies for long-term kidney graft survival in patients with IgA 
nephropathy.  Long-term kidney allograft tolerance can be achieved through 
establishment of mixed chimerism [8]. Mixed chimerism can be achieved by treating 















II. INTRODUCTION AND BACKGROUND     
   
    Several kidney diseases lead to complete kidney failure and require the afflicted 
patient to undergo a kidney transplant. One such kidney disease is IgA nephropathy 
(Berger’s Disease). IgA nephropathy is one of the most common forms of 
glomerulonephritis around the world [1] and is characterized by the presence of the 
immunoglobulin IgA deposits in the kidney [2]. Although cases of IgA nephropathy have 
been documented in every race, Asians, Caucasians, and men are most often affected. 
 
         Kidney Structure and Function 
  The kidney is made up of many nephrons, which filter the blood, ridding it of 
waste products and salts while regulating blood pressure, electrolytes, and blood pH [10].  
To understand the pathogenesis of IgA nephropathy, it is helpful to appreciate how a 
kidney normally functions. The kidney receives the blood to be filtered from the renal 
artery. As shown in Figure 1, this artery forms several branches that feed blood to each of 




      Figure 1 . The Renal Blood Supply That Delivers The Blood to Be Filtered. 
                              Adapted from [17].  
  
  Each of these nephrons has a renal corpuscle unit that contains a glomerulus. The 
glomerulus sits within an invaginated region known as Bowman’s capsule, as shown in 
Figure 2.  
 
Figure 2 . Normal Renal Corpuscle Unit. Adapted from  [18].  
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   The glomerulus is a tuft of fenestrated capillaries.  As depicted in Figure 3, blood 
to be filtered initially passes through the pores of the fenestrated capillaries, which are 
composed of endothelial cells [10].  
 
 
Figure 3. Cross Section of Glomerular Capillary with Basal Lamina.  
Adapted from [19]. 
 
   
  The pores of the capillary are 70-90nm in size, which allow larger molecules to be 
retained. The filtrate then encounters the basal lamina (glomerular basement membrane). 
Here several layers work in concert to further filter by molecule size and charge [10]. The 
lamina densa layer traps molecules larger than 69,000 Da while a lamina rara layer traps 
negatively charged particles. As shown in Figure 4, the filtrate that escapes the basal 
lamina layers must then pass through filtration slits created by podocyte cell pedicels.  
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Figure 4. Formation of Pedicals by Podocyte Cells, Which Form the Filtration Slits 
Adapted from [18]. 
 
  The filtrate that remains is composed of water, metabolites, ions 
(sodium/potassium), and small molecules (such as toxins). The remaining filtrate enters 
the Bowman’s space prior to becoming further modified by a network of tubules that 
concentrate the amounts of water and ions to form urine [10].  
 
        
  IgA Nephropathy 
   As shown in Figure 5, in a kidney compromised with IgA nephropathy the IgA 
becomes trapped and collects at the glomerular basement membrane of a glomerulus [1]. 
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Figure 5. IgA  and/or IgA Complexed with Antigen Becomes Trapped at the 
Glomerular Basement Membrane. Adapted from  [19]. 
 
  Over time, the accumulation of IgA at the glomeruli activates complement.  IgA 
activates complement via the mannan-binding lectin pathway [33]. During this type of 
complement activation the mannan lectin binds IgA via its carbohydrate recognition 
domain and activates complement C4 and C3 [33.]   The activated C4 and C3 
complement release vasoactive and chemotatic molecules such as C3b, which attract 
phagocytes such as neutrophils and macrophages to the glomeruli. The neutrophils and 
macrophages release inflammatory cytokines that damage the glomerular tissues leading 
to chronic inflammation and hindrance of blood filtration. The abnormal blood filtration 
leads to water retention, anemia, waste product accumulation, and high blood pressure. 
The ultimate outcome results in the shut down of nephrons and kidney failure. 
  Because a large volume of blood is in the kidney at any given time (estimated to 
be 1/3-1/5 of the total blood volume), large amounts of IgA would normally be present 
[30].  Since IgA is found primarily in mucosal tissues as secretory immunoglubulin and 
in the serum as monomeric IgA and does not equilibrate with body tissues as does IgG, it 
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is not surprising that IgA  is present on the luminal side of glomeruli.  Serum ratios of 
IgG:IgA range from 9:1 to 6:1 (as shown in Table 1). 
 




       Table 1. Physical Properties of Immunoglobulin Isotypes. Adapted from [5]. 
 




    
   As shown in Figure 6, serum IgG is routinely pinocytosed by the neonatal Fc 
receptor (FcRn) on endothelial cells and recycled into the serum [30] extending the half-




Figure 6 . The Pinocytosis of IgG by the FcRn Receptor. Adapted from [32]. 
 
    
 
  Since it is well established that the FcRn is involved in transcytosis, Haymann et 
al. suggest that it may play a role in reabsorption of IgG in the kidney [31]. No such 
recycling of IgA occurs since there are no Fc receptors for IgA on endothelial cells.  
However, normally intraglomerular macrophage-like mesangial cells continuously 
phagocytose the glomerular basement membrane to remove trapped molecules, e.g. 




IgA Structure and Proposed Migration Mechanisms that Lead to 




 IgA is an immunoglobulin found in both blood and mucosal epithelial surfaces. 




Figure 7: The Different Structures of IgA: The dimeric structure of IgA consists of two 
monomeric IgA molecules that are bound by disulfide bonds to a J chain (depicted by 




  IgA is also found in two forms IgA1 and IgA2.  As depicted in Figure 8, the 
difference in structure is based on the amino acids that make up the hinge region and 




Figure 8. The Differences in the Structures of IgA1 vs. IgA2: IgA1 has a Longer Hinge 
Region than IgA2. Adapted from [24]. 
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   IgA1 has been identified as the major type of IgA associated with IgA 
nephropathy [11]. IgA1 is composed of a longer and more flexible hinge region. The 
longer hinge region allows access to multiple antigen binding sites and thus speeds up the 
delivery of a pathogen to phagocytes. The longer hinge region however allows IgA1 to be 
more readily cleaved by pathogens producing IgA proteases and thus provides a 
mechanism for escaping phagocytosis. As depicted in Figure 9, IgA1 is cleaved at the 
hinge region, allowing IgA Fc and Fab fragments to remain separated in circulation [5]. 
These fragments may have the ability to bind directly to intraglomerular  
mesangial cells or antibodies to form immune complexes that contribute to the 
development of IgA nephropathy.  
 
  
Figure 9. The Cleavage of IgA1 by IgA Proteases. Adapted from [25]. 
   
 
  Novak et al. have shown that the IgA1 present in IgA nephropathy patients is 
galactose deficient at the hinge regions [12]. The trigger for the galactose deficiency is 
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unknown but is thought to arise from a mutation that is inherited or results from past 
infections. The galactose deficient IgA is recognized as a foreign antigen stimulating, 
antibodies that allow the formation of circulating immune complexes (CIC) [12]. When 
the sera of IgA nephropathy patients were analyzed for these CICs, IgG or IgA1 was 
found bound to the galactose deficient IgA1 [12]. The study found that the CIC from IgA 
nephropathy patients bound to the intraglomerular mesangial cells more efficiently then 
the CIC from healthy controls or normally glycosylated IgA1; the binding was thought to 
occur via an unknown IgA receptor [12]. These results not only suggested that 
underglycosylated IgA1 plays a role in the pathogenesis of IgA nephropathy but that IgA 
nephropathy patients have an IgA receptor on their mesangial cells that is specific for 
underglycosylated IgA1 [12]. 
 
Role of Streptococcus pyogenes in the Pathogenesis of IgA Nephropathy 
          IgA accumulates in the kidney during an upper respiratory infection with 
Streptococcus pyogenes [2].  Schmitt et al. proposed two mechanisms for entry of IgA 
into the kidney that centered on M proteins. M proteins are a virulence factor carried by 
Streptococcus pyogenes. As depicted in Figure 10, the M proteins are found embedded in 




Figure 10.  Location of M Protein within the Cell Wall Structure of Streptococcus 




The Potential Role of M Protein 
   M proteins are a virulence factor that allows Streptococcus pyogenes to establish  
infection in the body. The M proteins protect Streptococcus pyogenes by inhibiting C3 
convertases, which are generated in each of the three complement activation pathways [5] 
(Figure 11.1). In each of these pathways, component C3 is exposed to several proteolytic 
cleavage events until a pathogen is coated with complement C3b on its surface, 
facilitating phagocytosis of the pathogen.  C3 convertases cleave C3, leading to its 





Figure 11.1:  The Three Pathways of Complement Activation and The Generation of 
C3 Convertases That leads to the Phagocytosis of Pathogens. Adapted from [26]. 
 
As a result of M protein inhibition of the C3 convertase activity, Streptococcus pyogenes 






Figure 11.2 : The Inhibitory Effects of M Protein that Protect a Pathogen From 
Phagocytosis. Adapted from [26]. 
 
  The M proteins contain special binding regions for both immunoglobulins  IgA 
and IgG  [2]. The binding region for IgA is known as IgA-BR. Schmitt et al., proposed 
that during pathogenesis of Streptococcus pyogenes  these M proteins can become 
detached in circulation, allowing them to bind to IgA in circulation or bind IgA directly 
in the kidneys [2]. The M protein bound to IgA forms immune complexes that become 
trapped in the glomerular basement areas of the kidneys. Due to the anti-phagocytic 
activity of the M proteins, the immune complexes are unable to be digested by the 
intraglomerular mesangial cells, thereby causing extensive damage [2]. Kidneys of 
several IgA nephropathy patients and healthy patients were assessed for the presence of 
IgA binding M proteins. As shown in Figure 12, M proteins were only found in the 





Figure 12:  M Protein Deposits in the Mesangial Glomerular Areas in The Kidneys of 
IgA Nephropathy Patients. (M proteins were visualized by tagging their IgA binding 
regions (IgA-BR) with anti-IgABR (anti-sap) using immunohistochemical techniques. 
Brown stain= location of M protein). Adapted from [2]. 
 
 
  Their second theory was that the M proteins were colocalizing with IgA to form 
immune complexes in the kidney. To verify this the kidneys of IgA nephropathy patients 
that were positive for M proteins were examined for IgA deposits. As shown in Figure 
13, IgA deposits were found to be colocalizing in close proximity to the M proteins in the 
mesangial area of the glomerulus [2]. These findings further confirmed the ability of 
Streptococcal pyogene M proteins to be involved in the deposition of IgA in the kidney 






Figure 13 : IgA Colocalizes with M Protein Leading to the Formation of Immune 
Complexes in the Mesangial Areas of the Kidneys of IgA Nephropathy Patients. (IgA and 
IgABR of M proteins were tagged with 6nm & 10nm gold particles respectively and 




                                          New IgA Producing B-cells 
    Yuling et al. suggested that IgA nephropathy is an autoimmune disease caused 
by increased levels of CD19+ CD5+ B cells [3]. CD19+ CD5+ B cells are involved in 
manufacturing mucosal IgA, inflammatory cytokines, and auto reactive antibodies. Those 
patients with IgA nephropathy had a higher percentage of CD19+ CD5+ B cells in 
peripheral blood, kidney, and peritoneal fluids (12.6%, 11.3%, and 11.8% respectively) 
when compared to control subjects (1.1	  %,	  1.6	  %	  and	  1.8%	  respectively) and those 
afflicted with other kidney diseases such as systemic lupus erythematosis (3.1%,	  2.8%,	  	  




Figure 14.  The Percentages of CD19+ CD5+ B cells in Peripheral Blood (PB), Kidney 
(KB), and Peritoneal Fluids (PE). CS= control subjects; IgAN=IgA nephropathy patients; 




  Furthermore, the CD19+CD5+ B cells of  IgAN patients were producing higher 
levels of IgA (Figure 15), IFN-γ, and Baff  (B-cell activating factor) than the control 
subjects and systemic lupus erythematosus patients The higher levels suggested that the 
CD19+CD5+ B-cells were highly active in IgAN patients and maybe contributing to the 
pathogenesis of IgAN [3] 
 
 
Figure 15.  Percentage of IgA Produced by CD19+ CD5+ B cells in Peripheral Blood 
(PB), Kidney(KB), and Peritoneal Fluids (PE). CS= control subjects; IgAN=IgA 
nephropathy patients; SLE= systemic lupus erythematosus patients. P-value= < 0.01 in 




  The CD19+CD5+ B cells of IgAN patients were also resistant to Fas ligand -
induced apoptosis suggesting that the elevated levels of Baff were desensitizing the 
CD19+CD5+ B cells to apoptosis by promotion of proliferation and differentiation [3]. 
To modify the effects of the CD19+CD5+ B cells, the IgA nephropathy patients 
underwent treatment with corticosteroids and immunosuppressants. Following the 
treatment their CD19+ CD5+ B cells decreased in number (Figure 16) and became 
sensitive to Fas ligand-induced apoptosis [3]. 
 
 
Figure 16.  The Percentage of CD19+ CD5+ B cells in Peripheral Blood (PB), 
Kidney(KB), and Peritoneal Fluids (PE) of IgA Nephropathy (IgAN) Patients following 
Immunosuppressant Treatment. Adapted from [3] 
 
 
   These observations suggested that the larger numbers of CD19+ CD5+ B cells 
contributed to the establishment of IgA nephropathy by migrating to the kidney where 
they deposit high concentrations of IgA or auto reactive IgA leading to immune complex 
formation, complement activation, and inflammation that damage the glomerular tissues 
[3]. While these studies present possible mechanisms of the migration and accumulation 
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of IgA in the kidney, they do not suggest a treatment or method for removal of IgA from 
the kidney. Sadly, most patients afflicted with the disease undergo a kidney transplant as 
treatment.  
 
Renal Transplantation as a Treatment for IgA Nephropathy 
 Kidney transplants have been routinely performed since the 1950’s [4].  The body 
has the ability to survive and function with one working kidney, which allows more 
opportunities for transplants. However, the number of people in need of kidney 
transplants outnumbers the matching kidneys available.   
          While kidney transplants are performed routinely, they are quite complex in 
operation. Several conditions must be met when selecting a suitable donor. First the 
recipient and donor must match in major blood group type and Rh type [5]. As with 
blood transfusions, individuals with type O negative blood are considered universal 
donors. This type of matching is required in kidney transplants due to the vascular nature 
and blood filtration function of the organ. Mismatches in blood type would promote 
hyperacute rejection reactions [5] (Figure 18 A). In this type of reaction antibodies react 
with alloantigens on the endothelium of kidney graft and complement is fixed against A 
or B antigens on endothelial cells of blood vessels. This causes clotting and inflammation 
through out the transplanted kidney (Figure 18 A). The kidney stops functioning and dies 
due to the lack of blood flow.  Secondly the recipient and donor must match closely in 
HLA class one and two haplotypes [5]. This matching is especially difficult as HLA 
haplotypes are inherited and are unique to each individual. Matching is further 
complicated by the presence of pre-existing anti-HLA antibodies from past pregnancy, 
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blood transfusion, organ transplant, or cross-reactive bacterial antibodies. Mismatches in 
HLA haplotypes would promote both acute and chronic rejection [5] (Figure 17 B and 
C). During an acute rejection, alloreactive CD4 and CD8 T-cells are produced in a 
recipient against mismatched HLA type one and two haplotypes in the grafted kidney 
(Figure 17). The kidney tissues are attacked by these various rejection mechanisms, 
leading to inflammation and failure of the organ (Figure 18. B).  During a chronic 
rejection anti-HLA class I alloreactive antibodies attack the blood vessels of the graft. 
The blood vessels of the kidney thicken over time hindering blood flow to the kidney 
(Figure 18 C).  
 
 
Figure 17.  CD4 and CD8 T-cell Defensive Activity Toward Transplanted Donor Cells 




Figure 18 . Types of Graft Rejection Caused by the Actions of Alloreactive Recipient 
Antibodies, CD4 + T-cells, and CD8+ T-cells. Adapted from [28]. 
 
 
Immune Suppression for Allograft Survival 
 In most kidney transplant cases the donor and recipient cannot be exactly matched 
for all of the various HLA haplotypes and minor histocompatibility antigens. As a 
consequence, the recipient is required to take immunosuppressant drugs routinely to 
prevent the rejection of the newly grafted kidney [5]. Immunosuppressants are generally 
administered both before transplantation and following transplantation. There are three 
main classes of immunosuppressants and the recipient is generally given one drug from 
each class [5].  Class one immunosuppressants include a corticosteroid such as 
prednisone. A steroid is given to reduce inflammatory cytokine production, prevent entry 
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of lymphocytes to inflammation sites, and promote apoptosis of lymphocytes.  Class two 
immunosuppressants include cytotoxic drugs such as azathioprine. These are given to 
inhibit DNA replication so that alloantigen- activated lymphocyte proliferation is 
inhibited. Class three immunosuppressants include a T-cell activation inhibitor such as 
cyclosporine A. T-cell activation inhibitors are given to prevent granulocyte, T-cell, and 
B-cell activation. Combined these three classes present a powerful combination of drugs 
that prevent rejection of a grafted kidney, but long-term use leads to harmful side effects. 
Such effects include fluid retention, diabetes, damage to healthy dividing tissue, cancer, 
chronic primary infections, chronic secondary infections, and nephrotoxicity [5].  
 While kidney transplantation alone can prolong the life of an IgA nephropathy 
patient, the side effects of long-term immunosuppressants cannot be avoided. IgA 
nephropathy patients also are faced with a grim statistic of recurring IgA nephropathy. It 
has been estimated that over fifty percent of IgA nephropathy patients will see the return 
of IgA nephropathy in their newly transplanted kidney [6].   
 
Aims and Goals for the Future Treatment of IgA Nephropathy 
 It is clear that an alternative method to long-term immunosuppressant usage is 
needed with respect to kidney transplants. I am interested in using IgA nephropathy 
patients as a model to study alternative methods to long-term immunosuppression. If 
alternative methods could be developed, it would not only prolong graft survival but 
perhaps prevent the redevelopment of IgA in the newly transplanted graft. This research 
may also allow for more transplants to be carried out in those who cannot be successfully 







   Current literature has suggested several alternative treatments in transplantation 
that would allow for the avoidance of long-term immunosuppressant usage. Much of the 
current literature is focused on the use of hematopoietic stem cells as a means to avoid 
long-term immunosuppressant usage in transplant recipients.  
 
Hematopoietic Stem Cell Characteristics and Usage 
 Hematopoietic stem cells (HSC) are responsible for continuous renewal of blood 
and immune cells [13]. During the fourth through sixth weeks of a developing fetus, 
HSCs can be found in regions where the kidney, gonads, and aorta develop [14]. Here 
they divide and then migrate to the liver before migrating to the thymus and spleen. 
Shortly after birth and into adulthood they can be found in both bone marrow and 
peripheral blood.  As shown in Figure 19, HSCs can differentiate into many types of cells 




Figure 19 . Hematopoietic Stem Cells Give Rise to Leukocytes, Erythrocytes, and 
Thrombocytes. Adapted from [13]. 
 
  Hematopoietic stem cells (HSCs) have been commonly used to treat leukemia, 
lymphoma, hereditary blood disorders, and autoimmune diseases. Most recently they 
have been utilized to promote long-term graft survival in organ transplants. HSCs are 
divided into two types: long-term stem cells (LTSC) and short-term progenitor cells 
(STPC).  LTSC can self renew, differentiate, mobilize in and out of bone marrow to 
circulation, and can undergo apoptosis [13]. STPC can proliferate to form cells of the 
same type but cannot self renew or differentiate [13]. Due to these characteristics LTSCs 
are the main types of hematopoietic stem cells sought after in transplantation. LTSCs are 
selected for and extracted from HSC sources using known cell surface markers. As 
hematopoietic stem cells differentiate, they produce specific proteins that vary in both 
type and concentration [5]. These proteins can be identified in a hematopoietic stem cell 
and provide a marker for its developmental stage [13].  The HSC stem cell markers 
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include CD 34 +, CD59, Thy1 +, CD38 low/- , C-kit- -/low (CD117)  and lin -  ( HSC that 
are negative for lineage specific markers) [13]. These markers are associated with 
immature hematopoietic stem cells, which have not yet differentiated into any mature cell 
(ie plasma, B-cells, or T-cells) or have not yet committed to a particular cell lineage [15]. 
HSC cells that are positive for markers CD34+ and Thy1+ have been found to engraft 
quickly and with fewer complications [15]. The reason for the greater success in 
engraftment is unknown, but CD34 + and Thy1+ expressing HSC are associated with 
prothymocytes (T-cell precursor cells [15] and CD34 and Thy1 are involved in cell-cell 
adhesion [34].  These characteristics may allow these cells to enter the bone marrow 
sooner than other HSC cells and thus allow them to engraft quickly.  
Sources of Hematopoietic Stem Cells and Transplant Procedure 
  As shown in table 2, hematopoietic stem cells can be obtained in several ways for 
usage in organ transplants.  






  Most organ transplants utilize hematopoietic stem cells that have been taken from 
the peripheral blood of an intended matching organ donor [13]. Once the blood is drawn, 
it is subject to leukapheresis, which filters the blood, removing mononuclear cells. The 
mononuclear cells are further separated to select for LTSCs that contain HSC markers 
such as CD34+. Once the intended cell type has been selected it is cryopreserved until 
use [13]. Prior to receiving the donor HSCs, the recipient must undergo lethal irradiation 
to destroy their own immunologic cells [16]. The recipient is then given an intravenous 
injection of the donor HSCs cells either before or after their organ transplant. Initially, 
following the combined transplants the recipient is required to take immunosuppressive 
drugs. This allows the newly transplanted donor HSCs to travel to the bone marrow 
unharmed and begin engraftment, which generally occurs two-four weeks following a 
transplant [16]. 
 
The Significance of Mixed Chimerism  
  Organ transplants have been combined with a hematopoetic stem cell transplant. 
In these cases long-term graft survival was achieved without long-term 
immunosuppressant usage. The key to establishing this tolerance was marked by the 
establishment of mixed chimerism. Mixed chimerism is the ability of the donor and 
recipient hematopoietic stem cells to coexist indefinitely within the recipient [8]. In this 
manner, both the donor and recipient immunologic cells become tolerant of each other 
and remain non-combative. This peaceful harmony among the immunologic cells allows 
the newly transplanted organ to be tolerated and accepted.  
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 The first protocols for establishment of mixed chimerism in transplant recipients 
were carried out in animals [8]. As shown in Figure 20, the recipient first receives lethal 
irradiation of the entire body and thymus. This is done to destroy the recipient’s 
immunologic cells. Next, the recipient is given anti-thymocyte globulin to destroy any 
remaining alloreactive T-cells. Following these procedures, the recipient receives the 
organ needed and hematopoetic stem cells from the donor. The recipient is then initially 
placed on immunosuppressants to allow full engraftment of both the organ and 
hematopoietic stem cells. These protocols provide a general guideline for combined 
organ and hematopoietic stem cell transplant, however several modifications have been 
made in the way of timing, type of hematopoetic cell used, irradiation, and 




Figure 20:  Procedure for the Establishment of Mixed Chimerism in a Transplant 
Recipient. Adapted From [29]. 
 
 




  After the above procedure the hematopoietic stem cells of the donor are able to 
migrate to the bone marrow where they engraft and coexist with the recipient’s 
hematopoetic stem cells  (Figure 21) [29]. The donor and recipient hematopoetic 
progenitor cells then travel to the thymus [29]. Here they become thymic dendritic cells 
that are involved in clonal deletion of self-reactive T-cells. In successful cases of mixed 
chimerism, recipient reactive and donor reactive T-cells are eliminated, allowing the 
newly mature T-cells to be tolerant toward donor and recipient cells.  
 
Figure 21.  The Engraftment and Tolerance of Donor Hematopoetic Stem Cells in 




A Liver Transplant Leads to Graft Tolerance Via Hematopoietic Stem Cells.  
  The first review involves an unintentional bone marrow stem cell transplant [7]. 
In this case a nine-year-old girl had undergone a whole liver transplant after developing 
hepatitis. A twelve-year-old male who had died of a brain injury served as the liver 
donor. The patient and the donor were a close match in HLA haplotypes and blood type 
but differed in rhesus factor (Rh). Post transplantation the recipient received a 
combination of tacrolimus, prednisone, and azithioprine for immunosuppression. Nine 
months following the transplant the recipient’s blood type changed from type O Rh 
negative to that of O Rh positive, the donor’s type [7]. The recipient then developed 
hemolytic anemia.  A direct antiglobulin test was performed to evaluate development of 
autoimmune hemolytic anemia. The results confirmed that her red blood cells had 
become coated with IgG antibodies. As a result she was placed on prednisone to treat the 
hemolytic anemia. However the prolonged treatment caused adverse side effects and the 
hemolytic anemia returned when the prednisone dosage was decreased.  These findings 
and the abnormal change in blood type suggested that the recipient had developed mixed 
chimerism.  To confirm this possibility, an in situ hybridization analysis was performed 
on bone marrow and peripheral blood taken from the recipient. Fluorescent tagged probes 
were generated against X or Y chromosomal DNA and allowed to interact with the 
marrow or blood samples (Figure 22). It was confirmed that both male and female 





Figure 22.  Fluorescence In Situ Hybridization of X and Y Chromosomes on Bone 
Marrow Sample from Liver Transplant Recipient. ( X = Green, Y= Red). 
Adapted from [7] 
 
   Bone marrow myeloid, erythroid, and CD19 + B cells of the recipient were found 
to be male (XY) [7]. The peripheral blood of the recipient also contained high 
percentages of male (XY) T-cells, B-cells, granulocytes, and natural killer cells (94%, 
98%, 100%, and 100% respectively). These results led to the conclusion that she had 
developed mixed chimerism. The mixed chimerism was thought to have occurred from 
exposure to passenger hematopoietic stem cells left in the donor liver [7]. The hemolytic 
anemia was being induced by the recipient’s residual B-lymphocytes. Her B-lymphocytes 
were attacking her erythoid cells because they had become those of the male donor [7].    
All immunosuppressive treatment was discontinued to permit donor destruction of 
recipient residual B-lymphocytes and therefore prevent the production of antibodies 
against the donor’s erythroid cells [7].  In this manner they were able to allow her body to 
fully accept the liver graft.  Five years following the transplant, tests were performed to 
monitor mixed chimersim and tolerance of the recipient’s graft while off 
immunosuppressive treatment.  Peripheral blood was assessed for T-cell receptor 
excision circles (TRECs) that mark early T-cells derived from the thymus. The elevated 
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numbers of TRECs following the transplant indicated that the donor cells were engrafted 
and not involved in expansion in the peripheral blood (Figure 23) [7].  
 
 
Figure 23.  Elevated TREC Numbers in the Recipient Post Transplantation Suggest 




  Mixed lymphocytes culture analysis confirmed that the recipient’s lymphocytes 
were not reactive towards the donor’s lymphocytes. Taken together, these results 
indicated that long term mixed chimerism and graft tolerance had been established [7]. 
They also showed that graft tolerance could be established long-term without the use of 
immunosuppressants [7].  Furthermore I had the chance to follow up via email with the 
principal investigator Dr. Micheal Stormon who informed me that the patient is doing 
well and is currently immunosuppressant free. ( It has been approximately nine years 






A Hematopoetic Cell Transplant Combined with A Kidney Transplant 
Allows Long-Term Graft Survival without Immunosuppressants 
 
 
 The second review involves a case of an intentional hematopoietic stem cell 
transplant administered with a kidney transplant [8]. In this case a forty- seven year old 
man was the kidney transplant recipient. The man’s brother served as the kidney donor. 
The two men were a close match in both blood and HLA haplotypes. Six weeks before 
the transplant, the donor was given subcutaneous injections of granulocyte colony 
stimulating factor (GCSF) to stimulate migration of mononuclear cells from the bone 
marrow to peripheral blood. His blood was drawn and subjected to leukapheresis to select 
for mononuclear cells. The selected cells were further subjected to immunobead selection 
to obtain CD34+ hematopoietic progenitor cells [8].  On the day of the transplant, the 
recipient was given anti-thymocyte globulin to destroy T-cells and immunosuppressants 
(cyclosporine and prednisone). Following the transplant, the recipient received total 
irradiation of primary and secondary lymphoid tissues and was given an intravenous 
injection of donor mononuclear CD34+ HSC enriched with CD3+ cells. DNA genotyping 
of T-cells, B-cells, natural killer cells, and granulocytes derived from recipient peripheral 
blood was performed one month following transplantation to assay for mixed chimerism 
[8].  As shown in Figure 24, the recipient had a high percentage of donor immunological 
cells beginning one month following the transplant and persisting through the final 
analysis, indicating that mixed chimerism was present because the donor cells were not 




Figure 24.  The Percentage of Surviving Donor Cells in the Peripheral Blood of the 
Kidney Transplant Recipient. Adapted from [8]. 
 
   
   To further confirm mixed chimerism, mixed lymphocyte reactions were 
performed by culturing dentritic cells of the donor with mononuclear cells of the 
recipient.  As shown in Figure 25, prior to transplantation of both donor CD34+ 
hematopoetic progenitor cells and the kidney, the recipient’s cells were reactive to the 
donors [8]. However after the transplant the reactivity decreased, suggesting that mixed 





Figure 25.  Mixed Lymphocyte Reactions of The Recipient’s Mononuclear Cells with 
Donor Dendritic Cells. Adapted from [8]. 
 
 
   The mixed chimerism had initially been discovered thirty days after the transplant 
and continued through the final analysis of the study. The mixed chimerism had resulted 
from the combination of eliminating reactive recipient T-cells and the introduction of 
donor hematopoietic cells [8]. In this situation the recipient was allowed to maintain his 
own immunological cell repertoire while gaining a tolerance to the immunological cells 
of the recipient. This allowed the donor kidney to be fully accepted by the recipient and 
reactive T-cells eliminated. Following a kidney biopsy, which revealed no inflammation, 
the recipient’s immunosuppressant treatment was discontinued. This study was successful 
in establishing long-term graft survival through the use of hematopoietic stem cells, 
which prevented the use of long-term immunosuppressant usuage. I had the chance to 
follow up via email with the principal investigator Dr. Samuel Strober who informed me 
that the patient is doing well and currently remains immunosuppressant free. ( It has been 
approximately 5 years since the transplant)  
 
 35 
A Combined Bone Marrow and Kidney Transplant is Successful Despite 
Mismatched HLA Haplotypes. 
 
 The third study involved combining a kidney and bone marrow transplant in five 
patients [9]. All five patients mismatched their donor in HLA haplotypes. All patients 
received conditioning prior to their transplants. The pre-conditioning initially included 
thymic radiation and anti-CD2 monoclonal antibody to destroy reactive T-cells. 
Cyclophosphamide was then given to enhance engraftment of donor T cells followed by 
cyclosporine to suppress the immune system. Then hemodialysis was done to filter the 
blood of unwanted antigens [9]. On the day of the kidney transplant the recipients 
received an intravenous infusion of donor bone marrow and they were placed on 
cyclosporine, prednisone, and rituximab. The patients initially developed transient 
chimerism but long term mixed chimerism could not be achieved. The transient 
chimerism had been induced by the donor bone marrow [9]. The tolerance to the kidney 
persisted post chimerism because the reactive immunologic cells had been eliminated by 
thymic radiation [9]. Furthermore as engraftment of donor cells occurred, reactive T-cells 
were eliminated by central tolerance in the thymus [9]. In this way developing T-cells 
that were reactive to donor T-cells were eliminated. To confirm this theory, cell mediated 
lympholysis was carried out using CD8+ T-cells of the recipient and exposing them to 
antigens of the donor and a third party control. As shown in Figure 26, the recipient 
CD8+ T –cells were unresponsive toward the antigens of the donor following the 
transplant both during immunosuppressant usage and when immunosuppressants were 
withdrawn. (Note: variations in response to the third party control subject is due to the 
activity of immunosuppressants in the recipient or lack thereof, and specific reactivity 




Figure 26 . Cell Mediated Lympholysis Analysis Confirms that Recipient CD8+T-cells 
Became Unresponsive to Donor Antigens Following Kidney and Bone Marrow 
Transplants. Arrows= time at which the immunosuppressants were withdrawn  
( black=donor, Gray= third party control). Adapted from [9]. 
 
 
  The tolerance of the recipient CD8 + T cells towards the donor antigens suggested 
that CD4+ T-cells were tolerant as well and that immunosuppressive treatment may not 
be needed [9].  As shown in Figure 27, the recipients CD4+ T-cells were unreactive 
towards donor antigens following the transplant and remained unreactive following the 
withdrawal of immunosuppressants. 
 
Figure 27:  Mixed Lymphocyte Reactions of Recipient CD4+ T-cells to Donor and 
Healthy Subject Antigens Before Transplant , After Transplant and After Withdraw of 
Immunosuppressants. ( Dark blue= donor, Light blue = healthy subject, Arrows= 
immunosuppressants withdrawn). Adapted from [9]. 
 




   Due to these findings all of the patient’s immunosuppressant treatments were 
discontinued [9]. The persistent tolerance to the kidney grafts allowed four of the five 
recipients to remain free from all immunosuppressant usage. I had the chance to follow 
up via email with the principal investigator Dr. David Sachs who informed me that the 
patients are doing well and are currently immunosuppressant free. ( It has been 












































  These reviews taken together have led me to propose alternative measures in the 
treatment of IgA nephropathy. I propose that IgA nephropathy can be best treated with 
donor kidney allografts that are transplanted along with donor bone marrow stem cells. In 
transplanting the kidney along with hematopoietic cells I believe that full allograft 
acceptance can be achieved without the use of long-term immunosuppressants in IgA 
nephropathy patients. I suspect that mixed chimerism can be established in those IgA 
nephropathy patients who receive a transplant of both kidney and hematopoietic stem 
cells.  Since IgA nephropathy has been associated with IgA producing autoreactive B-
cells [3], I further suggest that the establishment of mixed chimerism may prevent the 
regeneration of IgA nephropathy in the newly transplanted renal graft. In this way, the 
recipient’s auto-reactive B-cells will initially be destroyed by irradiation. Remaining 
auto-reactive B cells should not react to the donor kidney because both donor and 
recipient auto-reactive T and B- cells are eliminated during the establishment of mixed 
chimerism [29].  If the IgA producing auto-reactive B-cells are eliminated, then immune 
complexes containing IgA will not be deposited in the newly grafted kidney.  
 Future approaches and interests would include further investigation of mixed 
chimerism and how it can be successfully established in IgA nephropathy patients. 
Additional investigation of IgA and why it is retained in the kidneys of IgA nephropathy 
patients would be needed. Research studies would include intraglomerular mesangial 
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cells and their potential role in the pathogenesis of IgA nephropathy. Brennan et al., have 
shown that intraglomerular mesangial cells can function as antigen presenting cells [35]. 
Intraglomerular mesangial cells may have the ability to present self –antigen that could 
contribute to the reoccurrence of IgA nephropathy in newly transplanted grafts. The 
establishment of mixed chimerism may provide to be a useful treatment in the prevention 
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